AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32064621 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus β‐D mannuronic acid (M2000)
Number of subjects: 34
Study 32064621 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 34
Study 36244652 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose losartan (150 mg/day)
Number of subjects: 3834
Study 36244652 — intervention group
Group type: COMPARATOR
Intervention: Low-dose losartan (50 mg/day)
Number of subjects: 3834
Study 36342424 — intervention group
Group type: EXPERIMENTAL
Intervention: Familias Unidas intervention
Number of subjects: 746
Study 36342424 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 746
Study 32735145 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg etanercept
Number of subjects: 550
Study 32735145 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg etanercept
Number of subjects: 550
Study 32735145 — intervention group
Group type: COMPARATOR
Intervention: methotrexate
Number of subjects: 550
Study 32169594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable-containing infant foods with fruit
Number of subjects: 22
Study 32169594 — intervention group
Group type: COMPARATOR
Intervention: Vegetable-containing infant foods without fruit
Number of subjects: 22
Study 35718565 — intervention group
Group type: EXPERIMENTAL
Intervention: MOST-Psych (psychological symptoms)
Number of subjects: 762
Study 35718565 — intervention group
Group type: EXPERIMENTAL
Intervention: MOST-DorT (symptoms due to disease or treatment)
Number of subjects: 762
Study 33480666 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 78
Study 33480666 — intervention group
Group type: COMPARATOR
Intervention: Book listening (control group)
Number of subjects: 78
Study 34922302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Sex Therapy (CBST)
Number of subjects: 116
Study 34922302 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment (Sildenafil Citrate + CBST)
Number of subjects: 116
Study 34922302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 33927121 — intervention group
Group type: EXPERIMENTAL
Intervention: (tissue inhibitor of metalloproteinases‐2)•(insulin‐like growth factor‐binding protein 7) patterns
Number of subjects: 810
Study 33901062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide anesthesia
Number of subjects: 830
Study 33901062 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide-free anesthesia
Number of subjects: 830
Study 32980608 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 84
Study 32980608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid simulation
Number of subjects: 84
Study 32980608 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 32218430 — intervention group
Group type: EXPERIMENTAL
Intervention: EVEN distribution (16.7% at breakfast, 32.8% at lunch, 31.3% at dinner, 19.2% at snacks; N=23)
Number of subjects: 47
Study 32218430 — intervention group
Group type: COMPARATOR
Intervention: UNEVEN distribution (15.4% at breakfast, 36.6% at lunch, 34.9% at dinner, 12.4% at snacks; N=24)
Number of subjects: 47
Study 32185886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian dynamic borrowing designs
Number of subjects: 0
Study 35276894 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Protein (HP) diet (1.2 g/kg BW)
Number of subjects: 121
Study 35276894 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Carbohydrate (LC) diet (28 en%)
Number of subjects: 121
Study 35276894 — intervention group
Group type: COMPARATOR
Intervention: Normal Protein (NP) diet (0.8 g/kg BW)
Number of subjects: 121
Study 35276894 — intervention group
Group type: COMPARATOR
Intervention: Normal Carbohydrate (NC) diet (40 en%)
Number of subjects: 121
Study 35276894 — intervention group
Group type: EXPERIMENTAL
Intervention: LEDpdr regime
Number of subjects: 121
Study 32624444 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diuretic strategy
Number of subjects: 160
Study 32624444 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate antigen 125-guided diuretic strategy
Number of subjects: 160
Study 32624444 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔUNa24h (change in urinary sodium at 24 hours)
Number of subjects: 160
Study 34930967 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep intervention
Number of subjects: 78
Study 34930967 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 78
Study 32300799 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics containing Bifidobacterium bifidum BGN4 and Bifidobacterium longum BORI for 12 weeks
Number of subjects: 63
Study 32300799 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 63
Study 32300799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 35339225 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorfenapyr LLINs
Number of subjects: 39307
Study 35339225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyriproxyfen LLINs
Number of subjects: 39307
Study 35339225 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperonyl butoxide LLINs
Number of subjects: 39307
Study 35339225 — intervention group
Group type: COMPARATOR
Intervention: Pyrethroid-only LLINs
Number of subjects: 39307
Study 34530310 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard walker
Number of subjects: 23
Study 34530310 — intervention group
Group type: EXPERIMENTAL
Intervention: Front‐wheeled walker with straight wheels
Number of subjects: 23
Study 34530310 — intervention group
Group type: EXPERIMENTAL
Intervention: Front‐wheeled walker with caster wheels
Number of subjects: 23
Study 34530310 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg dominance
Number of subjects: 23
Study 35856208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral intervention
Number of subjects: 200
Study 35856208 — intervention group
Group type: COMPARATOR
Intervention: Routine outpatient care
Number of subjects: 200
Study 34132599 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR test with CbVds-P1/P2 primers
Number of subjects: 27
Study 34132599 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR assay with CbVd1-F1/R1 primers
Number of subjects: 27
Study 34132599 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR with CbVd1-F1/R1 primers
Number of subjects: 27
Study 34132599 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequencing of PCR products
Number of subjects: 27
Study 34132599 — intervention group
Group type: EXPERIMENTAL
Intervention: GenBank deposition
Number of subjects: 27
Study 35229327 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior knowledge condition (participants know they can take snacks home)
Number of subjects: 64
Study 35229327 — intervention group
Group type: EXPERIMENTAL
Intervention: No prior knowledge condition (participants do not know they can take snacks home)
Number of subjects: 64
Study 32674229 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐whey protein solution (CHP)
Number of subjects: 40
Study 32674229 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTL)
Number of subjects: 40
Study 35094006 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg weekly
Number of subjects: 52
Study 35094006 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alendronate, received calcifediol and calcium-enriched diet)
Number of subjects: 52
Study 34340243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 2
Study 34340243 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (CSs)
Number of subjects: 2
Study 32429839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane combined with Remifentanil anesthesia
Number of subjects: 0
Study 32429839 — intervention group
Group type: COMPARATOR
Intervention: Propofol combined with Remifentanil anesthesia
Number of subjects: 0
Study 35799658 — intervention group
Group type: EXPERIMENTAL
Intervention: MSBP combined with FBP algorithm
Number of subjects: 60
Study 35799658 — intervention group
Group type: COMPARATOR
Intervention: Control group (FBP algorithm only)
Number of subjects: 60
Study 33586360 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib 12 mg on days 1–14 (repeated every 21 days)
Number of subjects: 165
Study 33586360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 33586360 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 165
Study 32032229 — intervention group
Group type: EXPERIMENTAL
Intervention: U+D (uphill-downhill training)
Number of subjects: 28
Study 32032229 — intervention group
Group type: COMPARATOR
Intervention: H (horizontal training)
Number of subjects: 28
Study 32032229 — intervention group
Group type: COMPARATOR
Intervention: C (control group)
Number of subjects: 28
Study 33875429 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBP‐PI‐HBr) 600 mg
Number of subjects: 24
Study 33875429 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBP‐PI‐HBr) 1200 mg
Number of subjects: 24
Study 33875429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33875429 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 24
Study 32694367 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cells reinfusion
Number of subjects: 12
Study 32694367 — intervention group
Group type: COMPARATOR
Intervention: Saline reinfusion (Control)
Number of subjects: 12
Study 32446170 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 69
Study 32446170 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training plus supplementation
Number of subjects: 69
Study 32446170 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation
Number of subjects: 69
Study 32446170 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 69
Study 34676521 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI) combined with standardized post-resuscitation care bundle (PRCB)
Number of subjects: 978
Study 34676521 — intervention group
Group type: COMPARATOR
Intervention: Standardized post-resuscitation care bundle (PRCB)
Number of subjects: 978
Study 32933452 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE) sessions (six 15-minute sessions) along with physical therapy
Number of subjects: 7
Study 32933452 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy with PNE
Number of subjects: 7
Study 35963005 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (ranibizumab with photodynamic therapy)
Number of subjects: 322
Study 35963005 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab monotherapy
Number of subjects: 322
Study 35963005 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of CPREG at month 3
Number of subjects: 322
Study 35963005 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of polypoidal lesion pulsation on ICGA
Number of subjects: 322
Study 34339536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu AuraOnce
Number of subjects: 43
Study 34339536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu AuraFlex
Number of subjects: 43
Study 32505866 — intervention group
Group type: EXPERIMENTAL
Intervention: Instagram
Number of subjects: 308
Study 32505866 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook
Number of subjects: 308
Study 32505866 — intervention group
Group type: COMPARATOR
Intervention: Control (matching game)
Number of subjects: 308
Study 37822045 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight collagen peptides
Number of subjects: 100
Study 37822045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33541288 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care of treatment & SBRT to all bone metastases
Number of subjects: 196
Study 33541288 — intervention group
Group type: COMPARATOR
Intervention: Standard care of treatment
Number of subjects: 196
Study 32773349 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0-T MRI
Number of subjects: 238
Study 32773349 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow FOV, standard-resolution CBCT
Number of subjects: 238
Study 32773349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no imaging)
Number of subjects: 238
Study 32773349 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental groups (CBCT and MRI)
Number of subjects: 238
Study 35875924 — intervention group
Group type: EXPERIMENTAL
Intervention: MHEP (Euphytose®)
Number of subjects: 31
Study 35875924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 34327227 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field Treatment (PEMF)
Number of subjects: 82
Study 34327227 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 82
Study 35730363 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel management intervention using PrEP coordinators and a web-based panel management tool
Number of subjects: 10
Study 33791385 — intervention group
Group type: EXPERIMENTAL
Intervention: Periocular injection of triamcinolone acetonide (TA) administered once every 3 weeks for a total of 3 times.
Number of subjects: 68
Study 33791385 — intervention group
Group type: COMPARATOR
Intervention: Subpalpebral injection of botulinum toxin type A (BTXA) given as a single administration.
Number of subjects: 68
Study 33994585 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Reactive Protein (CRP) and Sequential Organ Failure Assessment (SOFA) score at admission
Number of subjects: 150
Study 33994585 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-critical care group)
Number of subjects: 150
Study 36239414 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic Treatment (PAT)
Number of subjects: 227
Study 36239414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 227
Study 34498484 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) for VTE prevention
Number of subjects: 1008
Study 34498484 — intervention group
Group type: COMPARATOR
Intervention: Current routine assessment and practice
Number of subjects: 1008
Study 35978355 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated smoking cessation therapy consisting of weekly brief behavioural interventions and prescription-free nicotine replacement products (nicotine lozenges, patches, and chewing gum) for 16 weeks (with an option to extend by 8 weeks).
Number of subjects: 266
Study 35978355 — intervention group
Group type: COMPARATOR
Intervention: Standard care without any added interventions related to smoking cessation.
Number of subjects: 266
Study 35978355 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated smoking cessation therapy.
Number of subjects: 266
Study 33518321 — intervention group
Group type: COMPARATOR
Intervention: Glycyrrhiza polysaccharide (GCP) 0 mg/kg
Number of subjects: 600
Study 33518321 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhiza polysaccharide (GCP) 200 mg/kg
Number of subjects: 600
Study 33518321 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhiza polysaccharide (GCP) 500 mg/kg
Number of subjects: 600
Study 33518321 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhiza polysaccharide (GCP) 1,000 mg/kg
Number of subjects: 600
Study 33518321 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhiza polysaccharide (GCP) 1,500 mg/kg
Number of subjects: 600
Study 33518321 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (1 mg/kg body weight)
Number of subjects: 600
Study 33518321 — intervention group
Group type: COMPARATOR
Intervention: Saline (control for LPS)
Number of subjects: 600
Study 32756138 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacopuncture
Number of subjects: 0
Study 32756138 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 0
Study 34212181 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive-based contact investigation
Number of subjects: 3776
Study 34212181 — intervention group
Group type: COMPARATOR
Intervention: Household-based contact investigation
Number of subjects: 3776
Study 34597865 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevent Injury and Enhance Performance (PEP) warm-up
Number of subjects: 14
Study 34597865 — intervention group
Group type: COMPARATOR
Intervention: Bicycle ergometer warm-up
Number of subjects: 14
Study 33371139 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided paravertebral block
Number of subjects: 100
Study 33371139 — intervention group
Group type: COMPARATOR
Intervention: Traditional analgesia
Number of subjects: 100
Study 33724473 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement with simultaneous bone augmentation
Number of subjects: 40
Study 33724473 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant placement after ridge preservation
Number of subjects: 40
Study 33539635 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagal Nerve Stimulation (t-VNS), 4 hours per day for 4 weeks
Number of subjects: 20
Study 33539635 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagal Nerve Stimulation (t-VNS)
Number of subjects: 20
Study 36224694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology test
Number of subjects: 2967
Study 36224694 — intervention group
Group type: EXPERIMENTAL
Intervention: hr-HPV testing
Number of subjects: 2967
Study 36224694 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cervical cytology and hr-HPV test for triage
Number of subjects: 2967
Study 36224694 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative baseline hr-HPV
Number of subjects: 2967
Study 36410472 — intervention group
Group type: EXPERIMENTAL
Intervention: efdamrofusp alfa 2 mg
Number of subjects: 18
Study 36410472 — intervention group
Group type: EXPERIMENTAL
Intervention: efdamrofusp alfa 4 mg
Number of subjects: 18
Study 36410472 — intervention group
Group type: COMPARATOR
Intervention: aflibercept 2 mg
Number of subjects: 18
Study 36410472 — intervention group
Group type: EXPERIMENTAL
Intervention: efdamrofusp alfa 2 mg and 4 mg
Number of subjects: 18
Study 33139313 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out consent process
Number of subjects: 21
Study 35248683 — intervention group
Group type: EXPERIMENTAL
Intervention: BP + FI
Number of subjects: 249
Study 35248683 — intervention group
Group type: COMPARATOR
Intervention: BP
Number of subjects: 249
Study 35248683 — intervention group
Group type: COMPARATOR
Intervention: NS
Number of subjects: 249
Study 33454311 — intervention group
Group type: EXPERIMENTAL
Intervention: Function and Behavior Focused Care for the Cognitively Impaired (FBFC‐CI)
Number of subjects: 336
Study 33454311 — intervention group
Group type: COMPARATOR
Intervention: Function and Behavior Focused Care Education (FBFC‐ED)
Number of subjects: 336
Study 33816765 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC901
Number of subjects: 103
Study 33816765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 32498248 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day ubiquinol (Ubq100)
Number of subjects: 60
Study 32498248 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day ubiquinol (Ubq150)
Number of subjects: 60
Study 32498248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plc)
Number of subjects: 60
Study 35466009 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-point prefabricated orthosis and elastic tape
Number of subjects: 70
Study 35466009 — intervention group
Group type: COMPARATOR
Intervention: Cast immobilization
Number of subjects: 70
Study 33576735 — intervention group
Group type: COMPARATOR
Intervention: lemborexant 10 mg
Number of subjects: 949
Study 33576735 — intervention group
Group type: COMPARATOR
Intervention: lemborexant 5 mg
Number of subjects: 949
Study 33576735 — intervention group
Group type: EXPERIMENTAL
Intervention: lemborexant 5 mg and 10 mg
Number of subjects: 949
Study 35046055 — intervention group
Group type: EXPERIMENTAL
Intervention: IP cisplatin, IP rintatolimod (dsRNA, TLR3 ligand), oral celecoxib (COX-2 blocker), and IP IFNa at 2, 6, and 18 million units (MU) in cohorts 2, 3, and 4 respectively
Number of subjects: 12
Study 35046055 — intervention group
Group type: EXPERIMENTAL
Intervention: IP cisplatin, IP rintatolimod (dsRNA, TLR3 ligand), oral celecoxib (COX-2 blocker)
Number of subjects: 12
Study 34546139 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Patterns (HEPs)
Number of subjects: 96
Study 36504629 — intervention group
Group type: EXPERIMENTAL
Intervention: a-tDCS (anodal transcranial direct current stimulation)
Number of subjects: 36
Study 36504629 — intervention group
Group type: EXPERIMENTAL
Intervention: a-tDCS
Number of subjects: 36
Study 36504629 — intervention group
Group type: COMPARATOR
Intervention: s-tDCS (sham transcranial direct current stimulation)
Number of subjects: 36
Study 32805322 — intervention group
Group type: EXPERIMENTAL
Intervention: P–F4 nanoparticles
Number of subjects: 0
Study 34894781 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual resilience training
Number of subjects: 77
Study 34894781 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 77
Study 35646603 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based compassion course
Number of subjects: 276
Study 35646603 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural stress management course
Number of subjects: 276
Study 35646603 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 276
Study 33020646 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous dosing of dabrafenib and trametinib
Number of subjects: 206
Study 33020646 — intervention group
Group type: COMPARATOR
Intervention: Intermittent dosing of dabrafenib and trametinib
Number of subjects: 206
Study 33513714 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine protein hydrolysate (MPH) 3 g
Number of subjects: 86
Study 33513714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 32675537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics (2 postoperative doses)
Number of subjects: 243
Study 32675537 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 postoperative doses)
Number of subjects: 243